Autolus Therapeutics (NASDAQ:AUTL) Sees Large Volume Increase – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL) saw unusually-strong trading volume on Thursday . Approximately 5,096,923 shares traded hands during trading, an increase of 278% from the previous session’s volume of 1,349,308 shares.The stock last traded at $3.58 and had previously closed at $4.00.

Autolus Therapeutics Price Performance

The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $931.33 million, a PE ratio of -3.02 and a beta of 2.04. The company has a 50-day moving average of $4.02 and a 200 day moving average of $4.05.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Sell-side analysts predict that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Exchange Traded Concepts LLC lifted its position in Autolus Therapeutics by 9.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock worth $152,000 after acquiring an additional 3,740 shares during the period. Wealth Effects LLC increased its position in Autolus Therapeutics by 19.5% during the second quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock worth $171,000 after buying an additional 8,000 shares in the last quarter. EntryPoint Capital LLC increased its position in Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock worth $137,000 after buying an additional 11,456 shares in the last quarter. ProShare Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the second quarter valued at $43,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock valued at $139,000 after purchasing an additional 14,959 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.